BR112015011171A2 - compostos de pirrolopirimidina como inibidores da quinase - Google Patents

compostos de pirrolopirimidina como inibidores da quinase

Info

Publication number
BR112015011171A2
BR112015011171A2 BR112015011171A BR112015011171A BR112015011171A2 BR 112015011171 A2 BR112015011171 A2 BR 112015011171A2 BR 112015011171 A BR112015011171 A BR 112015011171A BR 112015011171 A BR112015011171 A BR 112015011171A BR 112015011171 A2 BR112015011171 A2 BR 112015011171A2
Authority
BR
Brazil
Prior art keywords
btk
inhibitors
compounds
conditions
kinase inhibitors
Prior art date
Application number
BR112015011171A
Other languages
English (en)
Inventor
J Loury David
Wang Longcheng
Chen Wei
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728514&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015011171(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of BR112015011171A2 publication Critical patent/BR112015011171A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo patente de invenção "compostos de pirrolopirimidina como inibidores da quinase" a presente invenção divulga compostos que formam ligações covalentes com tirosina quinase de bruton (btk). também são descritos na presente invenção os inibidores irreversíveis da btk. além disso, também são descritos na presente invenção os inibidores reversíveis da btk. composições farmacêuticas que incluem os compostos também são divulgadas. métodos de uso dos inibidores da btk são divulgados, sozinhos ou em combinação, com outros agentes terapêuticos para o tratamento de doenças ou condições autoimunes, doenças ou condições heteroimunes, câncer, incluindo linfoma e doenças ou condições inflamatórias.
BR112015011171A 2012-11-15 2013-11-14 compostos de pirrolopirimidina como inibidores da quinase BR112015011171A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261727031P 2012-11-15 2012-11-15
PCT/US2013/070164 WO2014078578A1 (en) 2012-11-15 2013-11-14 Pyrrolopyrimidine compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112015011171A2 true BR112015011171A2 (pt) 2017-07-11

Family

ID=50728514

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011171A BR112015011171A2 (pt) 2012-11-15 2013-11-14 compostos de pirrolopirimidina como inibidores da quinase

Country Status (24)

Country Link
US (3) US9096604B2 (pt)
EP (1) EP2920180A4 (pt)
JP (1) JP2015537033A (pt)
KR (1) KR20150084923A (pt)
CN (1) CN104854107A (pt)
AR (1) AR093518A1 (pt)
AU (1) AU2013344656A1 (pt)
BR (1) BR112015011171A2 (pt)
CA (1) CA2890934A1 (pt)
CL (1) CL2015001268A1 (pt)
CR (1) CR20150263A (pt)
DO (1) DOP2015000108A (pt)
EA (1) EA201590855A1 (pt)
HK (1) HK1215253A1 (pt)
IL (1) IL238728A0 (pt)
MA (1) MA38183A1 (pt)
MX (1) MX2015006168A (pt)
NI (1) NI201500067A (pt)
PE (1) PE20151495A1 (pt)
PH (1) PH12015501067A1 (pt)
SG (1) SG11201503842PA (pt)
TN (1) TN2015000174A1 (pt)
TW (1) TWI522359B (pt)
WO (1) WO2014078578A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US8962831B2 (en) 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
KR20150015021A (ko) 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
WO2014039899A1 (en) 2012-09-10 2014-03-13 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
PE20151495A1 (es) * 2012-11-15 2015-10-23 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas
EP2970205B1 (en) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
JP6615752B2 (ja) * 2013-09-30 2019-12-04 グアンジョウ・イノケア・ファーマ・テク・カンパニー・リミテッド Ｂｔｋの置換ニコチンイミド阻害剤およびそれらの調製、ならびにがん、炎症および自己免疫疾患の治療における使用
BR112016018948B1 (pt) 2014-02-21 2023-01-17 Principia Biopharma Inc Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
MA41197B1 (fr) 2014-12-18 2021-01-29 Principia Biopharma Inc Traitement de le pemphigus
RU2017133990A (ru) 2015-03-03 2019-04-05 Фармасайкликс Элэлси Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2017027883A1 (en) * 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
EA201890730A1 (ru) * 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
US10023579B2 (en) 2015-12-16 2018-07-17 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
CN107513068A (zh) * 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
MA45547A (fr) 2016-06-29 2019-05-08 Principia Biopharma Inc Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
MX2019003091A (es) * 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
CN106588937B (zh) * 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
CN106946896B (zh) * 2017-03-30 2019-05-21 成都知普莱生物医药科技有限公司 呋喃并[2,3-d]嘧啶-4-胺衍生物
IT201700099690A1 (it) * 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio
JP2021524835A (ja) 2018-04-05 2021-09-16 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Ａｘｌキナーゼ阻害剤およびその使用
MX2020010556A (es) 2018-04-13 2021-03-02 Sumitomo Pharma Oncology Inc Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
WO2020166680A1 (ja) * 2019-02-15 2020-08-20 大鵬薬品工業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－アミン誘導体
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN111825674A (zh) * 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113493439B (zh) * 2020-03-20 2022-10-14 深圳市塔吉瑞生物医药有限公司 取代的丙烯酰胺衍生物及其组合物及用途
CN113527300B (zh) * 2020-06-04 2023-02-03 广州百霆医药科技有限公司 布鲁顿酪氨酸蛋白激酶抑制剂
WO2022109551A1 (en) * 2020-11-17 2022-05-27 Relay Therapeutics, Inc. Src inhibitors and uses thereof
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023078413A1 (zh) * 2021-11-04 2023-05-11 微境生物医药科技(上海)有限公司 Fgfr2抑制剂、及其制备方法和医药用途
US20230277424A1 (en) * 2022-03-03 2023-09-07 Profounda Health And Beauty Inc. Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
DE69918089T2 (de) 1998-04-17 2005-07-14 Parker Hughes Institute, St. Paul Btk inhibitoren und verfahren zur identifizierung und verwendung
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CN1390219A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的吡唑并嘧啶类
DE60014130T2 (de) 1999-10-06 2006-03-09 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
CA2390857A1 (en) 1999-11-30 2001-06-14 Fatih M. Uckun Inhibitors of collagen-induced platelet aggregation
CA2394650A1 (en) 1999-12-17 2001-06-21 Chi B. Vu Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
EP1345592A2 (en) 2000-12-06 2003-09-24 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
CA2810339A1 (en) 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
NZ532579A (en) 2001-11-21 2006-11-30 Sunesis Pharmaceuticals Inc Methods for ligand discovery based on tethering process
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
JP2005536533A (ja) 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2005000197A2 (en) 2003-04-11 2005-01-06 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN1898240B (zh) 2003-10-15 2011-08-03 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
AU2005228845A1 (en) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
CA2581375A1 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
AU2005290028A1 (en) 2004-09-28 2006-04-06 Janssen Pharmaceutica, N.V. Substituted dipiperdine CCR2 antagonists
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
KR101357524B1 (ko) 2005-03-10 2014-02-03 질레드 코네티컷 인코포레이티드 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
DE602006019088D1 (de) 2005-05-13 2011-02-03 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
TWI522337B (zh) 2005-06-22 2016-02-21 普雷辛肯公司 用於激酶調節的化合物及方法及其適應症
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
US20080261975A1 (en) 2005-11-12 2008-10-23 Joerg Martin Bentzien Tec Kinase Inhibitors
CN101421269A (zh) 2006-01-13 2009-04-29 环状药物公司 酪氨酸激酶抑制剂及其用途
EP1984030B1 (en) 2006-01-30 2013-05-08 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
NZ571182A (en) 2006-04-04 2010-09-30 Univ California Pyrazolo[3,4-d]pyrimidines
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
SI2526934T1 (sl) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2561875A3 (en) 2007-03-28 2013-06-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2214486A4 (en) 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
EP2205564B1 (en) 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
MX2011002484A (es) 2008-09-05 2011-09-26 Avila Therapeutics Inc Algoritmo para diseñar inhibidores irreversibles.
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
AU2010295690B2 (en) 2009-09-16 2016-07-28 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TWI535716B (zh) 2010-05-31 2016-06-01 Ono Pharmaceutical Co Purine ketone derivatives
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
AU2011269989B2 (en) 2010-06-23 2014-12-11 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
BR112013003388A2 (pt) 2010-08-10 2016-07-12 Celgene Avilomics Res Inc sal de besilato de um inibidor de btk
US8962831B2 (en) * 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
KR20150015021A (ko) 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
MX368112B (es) * 2012-06-18 2019-09-18 Principia Biopharma Inc Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
PE20151495A1 (es) * 2012-11-15 2015-10-23 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas
US20160113932A1 (en) 2013-05-30 2016-04-28 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP3027192A4 (en) 2013-08-02 2017-03-22 Pharmacyclics, LLC Methods for the treatment of solid tumors
TWI660739B (zh) 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
CN106008516A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
US20150238490A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations

Also Published As

Publication number Publication date
TWI522359B (zh) 2016-02-21
KR20150084923A (ko) 2015-07-22
MX2015006168A (es) 2015-08-10
US20150239897A1 (en) 2015-08-27
US20160375026A1 (en) 2016-12-29
CN104854107A (zh) 2015-08-19
US20140142126A1 (en) 2014-05-22
CA2890934A1 (en) 2014-05-22
TN2015000174A1 (en) 2016-10-03
MA38183A1 (fr) 2017-03-31
PH12015501067A1 (en) 2015-08-10
HK1215253A1 (zh) 2016-08-19
IL238728A0 (en) 2015-06-30
US9096604B2 (en) 2015-08-04
JP2015537033A (ja) 2015-12-24
PE20151495A1 (es) 2015-10-23
EP2920180A1 (en) 2015-09-23
AU2013344656A1 (en) 2015-06-04
SG11201503842PA (en) 2015-06-29
EP2920180A4 (en) 2016-04-13
DOP2015000108A (es) 2015-06-30
WO2014078578A1 (en) 2014-05-22
US9540385B2 (en) 2017-01-10
TW201425315A (zh) 2014-07-01
CL2015001268A1 (es) 2015-07-10
AR093518A1 (es) 2015-06-10
EA201590855A1 (ru) 2015-11-30
CR20150263A (es) 2015-08-24
NI201500067A (es) 2016-02-15

Similar Documents

Publication Publication Date Title
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
BR112014026703A2 (pt) inibidores de dna-pk
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112014016163A8 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
BR112015027951A8 (pt) arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112015019412A2 (pt) inibidores de bace1
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento
BR112015022000A8 (pt) preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação
TR201201022A2 (tr) Akciğer hastalıkları, karaciğer hastalıkları ve çeşitli enfeksiyonların semptomatik ve/veya terapötik tedavisinde kullanılan farmasötik bileşimler.
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]